Skip to main content
. 2020 Sep 1;12(9):970. doi: 10.3390/v12090970

Table 1.

Number of doses of inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV) and level of neutralizing antibodies against polioviruses types 1, 2 and 3 in the sera of the contacts (arranged in accordance of the poliovaccine doses acquired).

The Contacts (Age in Months at the Time of the Acute Flaccid Paralysis (AFP) Case Detection) Number of IPV (+OPV) Doses before the First Serological Examination Antibody Titer (7–8 October 2014) against Poliovirus Serotype: Number of IPV Doses between Two Serological Examinations Antibody Titer (24 November 2014) against Poliovirus Serotype:
1 2 3 1 2 3
C-4 (23) 2 (+3) 1:64 1:256 1:32 0 ND *** ND ND
C-5 (41) 2 (+3) <1:8 1:128 <1:8 0 <1:8 1:256 <1:8
C-6 * (31) 2 (+3) 1:512 1:512 1:1024 0 1:256 1:256 1:512
C-7 (31) 3 (+2) 1:512 1:512 1:512 0 1:512 1:256 1:256
C-8 (33) 3 (+2) 1:32 1:128 1:256 0 1:64 1:128 1:128
C-9 (41) 3 (+2) 1:64 1:64 1:16 0 1:64 1:64 1:8
C-10 (36) 4 (+1) 1:512 1:512 1:128 0 1:256 1:512 1:256
C-11 (12) 2 (+1) 1:32 1:64 1:16 0 1:16 1:64 1:16
C-12 (13) 2 (+1) 1:64 1:64 1:512 1 1:512 1:512 1:512
C-13 (30) 6 1:64 1:256 >1:1024 0 1:64 1:128 1:256
C-14 (25) 6 1:128 1:128 1:128 0 1:64 1:128 1:64
C-15 (44) 5 >1:1024 1:512 1:512 0 >1:1024 1:512 1:512
C-16 * (25) 5 1:512 1:512 1:256 0 1:128 1:256 1:128
C-17 (31) 5 1:64 1:32 1:512 0 1:32 1:64 1:256
C-18 (41) 5 1:64 1:128 1:256 0 1:64 1:256 1:128
C-19 (47) 5 1:32 1:256 1:64 0 1:64 1:256 1:64
C-20 (20) 5 1:64 1:128 1:64 0 1:64 1:128 1:64
C-21 (33) 5 1:32 1:128 1:16 0 1:16 1:64 <1:8
C-22 (24) 4 >1:1024 1:1024 1:256 0 1:512 1:256 1:128
C-23 (21) 4 1:64 1:128 1:256 0 1:256 1:64 1:256
C-2 ** (22) 4 1:64 1:128 1:256 0 1:16 1:16 1:128
C-1 ** (20) 4 <1:8 <1:8 1:64 1 1:64 1:16 1:64
C-24 (21) 3 1:1024 1:256 1:512 0 1:256 1:256 1:128
C-25 (11) 3 1:256 1:512 1:256 0 1:32 1:128 1:64
C-26 * (23) 3 1:256 1:256 1:512 0 1:128 1:256 1:128
C-27 (52) 2 1:512 1:1024 1:512 1 1:128 1:256 1:512
C-28 (9) 2 1:256 1:256 1:128 1 1:256 1:256 1:64
C-29 (10) 2 1:64 1:256 1:128 1 1:64 1:256 1:512
C-30 (43) 2 1:32 1:256 1:256 1 1:16 1:128 1:512
C-31 (11) 2 1:16 1:32 1:256 1 1:128 1:128 1:256
C-32 (9) 2 1:32 1:128 1:64 1 1:256 1:512 1:256
C-33 (9) 2 <1:8 1:16 1:256 1 1:8 1:32 1:256
C-34 (14) 2 <1:8 <1:8 1:128 1 1:64 1:32 1:256
C-35 * (5) 1 1:512 1:512 1:128 1 1:256 1:256 1:16
C-36 (1) 1 1:64 1:128 1:64 1 1:512 1:512 1:256
C-37 (24) 1 1:32 1:16 1:8 1 1:128 1:128 1:32
C-38 (3) 1 1:8 1:64 1:32 1 1:256 1:256 1:256
C-39 (38) 1 1:8 1:64 1:16 1 1:128 1:64 1:8
C-40 (13) 1 <1:8 1:8 1:128 1 1:64 1:64 1:512
C-41 (1) 1 <1:8 1:32 <1:8 1 1:128 1:64 1:128
C-42 (4) 1 <1:8 1:8 <1:8 2 1:64 1:128 1:32
C-43 (4) 1 <1:8 <1:8 <1:8 1 1:64 1:64 1:64
C-44 (23) 1 <1:8 1:8 1:256 0 ND ND ND
C-45 (1) 1 <1:8 <1:8 <1:8 0 ND ND ND
C-46 (0) 0 <1:8 <1:8 <1:8 2 1:16 1:16 <1:8
C-47 (35) 0 <1:8 <1:8 <1:8 2 1:8 <1:8 1:8
C-48 (13) 0 <1:8 <1:8 <1:8 2 <1:8 <1:8 1:8
C-49 (2) 0 <1:8 <1:8 <1:8 2 <1:8 <1:8 <1:8
C-50 (6) 0 <1:8 <1:8 <1:8 2 <1:8 <1:8 <1:8
C-51 (7) 0 <1:8 <1:8 <1:8 2 <1:8 <1:8 <1:8
C-52 (8) 0 <1:8 <1:8 <1:8 2 <1:8 <1:8 <1:8
C-53 (16) 0 <1:8 <1:8 <1:8 2 <1:8 <1:8 <1:8

* Children living in the same room with the patient; ** Poliovirus excretors; *** ND—not done, sera were not collected and investigated.